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We kindly disagree with the comments of Dr. Jelliffe on the
use of digoxin in critically ill patients with atrial fibrillation
(AF) based on the review article “Management of Atrial
Fibrillation in Critically Ill Patients” [1].
Our daily experience in treating severely ill patients with
new-onset AF shows that digoxin is helpful in reducing the
heart rate (rate-control strategy) but is not useful for convert-
ing AF into sinus rhythm (rhythm-control strategy). This is
in line with the current guidelines of the European Society
of Cardiology [2] that state that “digoxin is ineffective for
AF termination.” Based on multiple negative randomized
placebo-controlled studies, the guidelines give a class III A
recommendation for converting new-onset AF with digoxin.
The 4 patients reported by Roger Jelliffe have, though inter-
esting, only anecdotal value.
Furthermore, Dr. Jelliffe disagrees with our statement that
serum levels of digoxin are recommended to support the
diagnosis of intoxication but are not very helpful for titrating
dose, as plasma levels do not correlate well with clinical
response. He suggests measurements of plasma levels of
digoxin combined with the use of the BestDose software to
calculate the optimal regimen. However, in his publication
Dr. Jelliffe states that “the range of serum digoxin concentra-
tions generally regarded as being therapeutic is often said to
be from about 0.5 to 2.0 ng/mL (. . .) a few patients tolerate
serum digoxin concentrations well over 3 ng/mL, and actually
as high as 6.5 ng/mL,without any toxicity (. . .) patients withAF
might require their own separate therapeutic ranges or target
concentrations.”
This further supports our statement that digoxin should
be titrated based on clinical response and not aiming at a
predefined serum concentration. The reported method for
adjusting the dose of digoxin using the BestDose software
is interesting but its broad implementation in daily clinical
practice in ICUs is unfortunately not in sight.
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